Clinical trials: Ductal Carcinoma In Situ
Breast Cancer
Simvastatin and Anastrozole in Treating Postmenopausal Women With Ductal Carcinoma In Situ or Invasive Breast Cancer
RATIONALE: Chemoprevention is the use of certain drugs to keep cancer from forming, growing, or coming back. The use of simvastatin and anastrozole may stop cancer from forming, growing, or coming back in patients with invasive…
- Trial name
- NCT00354640
- Testing
- anastrozole, simvastatin, pharmacological study
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Breast Cancer
Fulvestrant or Tamoxifen in Treating Postmenopausal Women Who Are Undergoing Surgery for Ductal Carcinoma in Situ of the Breast
RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using fulvestrant or tamoxifen may fight breast cancer by blocking the use of estrogen by the tumor cells.
- Trial name
- NCT00126464
- Testing
- fulvestrant, tamoxifen citrate, conventional surgery
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Cedars-Sinai Medical Center
Ductal Breast Carcinoma in Situ, Lobular Breast Carcinoma in Situ
Hormone Therapy Or Chemotherapy Before Surgery Based on Gene Expression Analysis in Treating Patients With Breast Cancer
This randomized pilot clinical trial studied whether the Oncotype DX gene expression "Recurrence Score" (RS) would be useful for helping make a decision about which type of pre-operative treatment, hormone therapy or chemotherapy…
- Conditions
- Ductal Breast Carcinoma in Situ, Lobular Breast Carcinoma in Situ, Stage II Breast Cancer, Stage IIA Breast Cancer
- Trial name
- NCT01293032
- Testing
- Neoadjuvant Therapy, Therapeutic Conventional Surgery, Laboratory Biomarker Analysis
- Where
- 8 sites in United States, Canada
- Volunteers
- 59 people
- Sponsor
- Virginia Commonwealth University
Breast Neoplasms
Single-Fraction Very Accelerated Partial Breast Irradiation (sfVAPBI)
To investigate clinical outcomes, late side effects, and cosmetic results of a single-fraction very accelerated partial breast irradiation as postoperative local treatment for the treatment of early stage breast cancer.
- Trial name
- sfVAPBI (NCT07067437)
- Testing
- single-fraction very accelerated partial breast irradiation
- Where
- 23 sites in France, Germany and 7 more
- Volunteers
- 250 people
- Sponsor
- National Institute of Oncology, Hungary
Breast Cancer, DCIS
Genotype and Phenotype Guided Supplementation of TAMoxifen Standard Therapy With ENDOXifen in Breast Cancer Patients
In hormone-receptor positive breast cancer or DCIS (ductal carcinoma in situ) tamoxifen remains an important treatment option for patients before menopause and those patients after menopause who cannot be treated with…
- Trial name
- TAMENDOX (NCT03931928)
- Testing
- (Z)-Endoxifen supplementation according to genotype, (Z)-Endoxifen supplementation according to plasma levels
- Where
- 40 sites in Germany
- Volunteers
- 356 people
- Sponsor
- Robert Bosch Gesellschaft für Medizinische Forschung mbH (RBMF)
Breast Cancer
Contrast-Enhanced MRI for the Characterization of Ductal Carcinoma in Situ (DCIS)
*REFERRALS TO THIS TRIAL MUST BE THROUGH BREAST CARE CLINICIANS ONLY* RATIONALE: Diagnostic procedures, such as contrast-enhanced MRI, may help find and diagnose ductal carcinoma in situ.
- Trial name
- NCT00804128
- Testing
- Magnetic Resonance Imaging (MRI), Gadavist
- Where
- United States
- Volunteers
- 76 people
- Sponsor
- University of California, San Francisco
Ductal Carcinoma in Situ
Evaluation of Novel Iron-based Lymphatic Mapping Agent, Magtrace, for Delayed Sentinel Lymph Node Biopsy (SLNB) in Ductal Carcinoma In-Situ (DCIS)
The standard surgical approach for all patients undergoing mastectomy for the treatment of non-invasive, ductal carcinoma in situ (DCIS) is to perform axillary lymph node staging through use of a traditional sentinel lymph node…
- Trial name
- NCT06868238
- Testing
- Magtrace
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Florida
Breast Cancer
Women At Risk: The High Risk Breast Cancer Program
The purpose of this study is to increase understanding of women who are at high risk for developing breast cancer. Data from this group will be collected and entered into a registry.
- Trial name
- WAR (NCT01034891)
- Where
- 2 sites in United States
- Volunteers
- 2,000 people
- Sponsor
- New York Presbyterian Hospital
Breast Cancer
Combination Chemotherapy With or Without Trastuzumab Followed By an Autologous Stem Cell Transplant and Radiation Therapy in Treating Patients With Stage III or Stage IV Breast Cancer
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00182793
- Testing
- trastuzumab, carboplatin, cyclophosphamide
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- City of Hope Medical Center
Ductal Carcinoma in Situ, Lobular Carcinoma in Situ
CAN1012 in Pre-Malignant DCIS and LCIS
This is a Phase I/Ib study evaluating CAN1012 in patients with ductal carcinoma in situ and lobular carcinoma in situ.
- Trial name
- NCT07408856
- Testing
- CAN1012
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Providence Health & Services
Breast Carcinoma, Breast Ductal Carcinoma in Situ
A Patient Navigation Program for Addressing Disparities in Breast Cancer Care
This clinical trial evaluates a patient navigation program for addressing disparities in breast cancer care. The navigation program is designed to help improve patient knowledge about clinical and supportive care services…
- Trial name
- NCT06350500
- Testing
- Patient Navigation, Questionnaire
- Where
- United States
- Volunteers
- 126 people
- Sponsor
- Roswell Park Cancer Institute
Benign Breast Neoplasm, Ductal Breast Carcinoma In Situ
Study of Docosahexaenoic Acid (DHA) in Triple Negative Breast Cancer Survivors
This randomized phase II trial studies how well docosahexaenoic acid works in preventing recurrence in breast cancer survivors. Docosahexaenoic acid supplement may prevent recurrence in breast cancer survivors.
- Conditions
- Benign Breast Neoplasm, Ductal Breast Carcinoma In Situ, Invasive Breast Carcinoma, Lobular Breast Carcinoma In Situ
- Trial name
- NCT01849250
- Testing
- Docosahexaenoic Acid
- Where
- 4 sites in United States
- Volunteers
- 65 people
- Sponsor
- National Cancer Institute (NCI)
Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage 1 Breast Cancer AJCC v8
Pre-operative SABR With and Without Caloric Restriction for Early Stage Breast Cancer
This phase II trial studies the effect of calorie reduction while undergoing stereotactic ablative radiation therapy in treating patients with breast cancer.
- Conditions
- Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage 1 Breast Cancer AJCC v8, Anatomic Stage 2 Breast Cancer AJCC v8, Anatomic Stage 3 Breast Cancer AJCC v8
- Trial name
- NCT04959474
- Testing
- Best Practice, Stereotactic Body Radiation Therapy, Resection
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Thomas Jefferson University
Breast Cancer
Radiofrequency Ablation in Treating Patients With Early Invasive Breast Cancer or Ductal Carcinoma in Situ
RATIONALE: Radiofrequency ablation uses a high-frequency, electric current to kill tumor cells. Giving radiofrequency ablation before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be…
- Trial name
- NCT00388115
- Testing
- conventional surgery, neoadjuvant therapy, radiofrequency ablation
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of California, Davis
Breast Cancer, Breast Cancer Female
Partial Chest Wall Radiation Therapy After Surgery for Lymph Node Negative Breast Cancer
The standard treatment for breast cancer when cancer cells were found near or within the margins of the tissue that is removed during breast surgery, is radiation of the entire chest wall.
- Conditions
- Breast Cancer, Breast Cancer Female, DCIS, Stage II Breast Cancer
- Trial name
- NCT05436808
- Testing
- Partial Chest Wall Radiation Therapy
- Where
- United States
- Sponsor
- Stony Brook University
Breast Cancer, Precancerous Condition
Flaxseed in Preventing Breast Cancer in Premenopausal Women at Risk of Developing Breast Cancer
RATIONALE: Ground flaxseed may prevent breast cancer in premenopausal women at increased risk of developing primary breast cancer.
- Trial name
- NCT00794989
- Testing
- Ground Flaxseed, No Intervention
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- Roswell Park Cancer Institute
Invasive Breast Cancer (Stage I-III), Ductal Carcinoma in Situ
Naltrexone RCT for Treatment-Emergent Fatigue in Patients Receiving Radiation Therapy for Breast Cancer
Naltrexone is a drug which blocks some effects of chemicals called beta-endorphins that are made in the body. Beta-endorphins can be made in response to stress, injury, and also pleasurable activities.
- Conditions
- Invasive Breast Cancer (Stage I-III), Ductal Carcinoma in Situ, Lobular Carcinoma in Situ, Lobular Carcinoma
- Trial name
- NCT02137252
- Testing
- Naltrexone, Sugar Pill
- Where
- 2 sites in United States
- Volunteers
- 3 people
- Sponsor
- Dana-Farber Cancer Institute
DCIS
Preoperative Palbociclib in Patients With DCIS of the Breast That Are Candidates for Surgery
This is a feasibility study which will evaluate the effects of pre-operative treatment of DCIS of the breast with palbociclib. Patients with biopsy-proven DCIS are eligible for the study.
- Trial name
- WI223281 (NCT03535506)
- Testing
- Palbociclib
- Where
- 2 sites in United States
- Volunteers
- 17 people
- Sponsor
- Georgetown University
Atypical Ductal Breast Hyperplasia, Lobular Carcinoma in Situ (LCIS)
Breast Cancer Chemoprevention by SOM230, an IGF-I Action Inhibitor: A Proof of Principle Trial
Atypical ductal hyperplasia (ADH) and atypical lobular hyperplasia (ALH) increases breast cancer risk. In post menopausal women, SERMS are standard chemopreventive agents.
- Conditions
- Atypical Ductal Breast Hyperplasia, Lobular Carcinoma in Situ (LCIS), Atypical Lobular Hyperplasia (ALH) of Breast
- Trial name
- NCT01372644
- Testing
- SOM 230 / Pasireotide
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- NYU Langone Health
Breast Neoplasms, Carcinoma, Ductal
Spect Analysis of Cardiac Perfusion Changes After Whole Breast/Chest Wall Radiation Therapy With ABC
Cardiac perfusion changes have been seen after whole breast / chest wall irradiation for breast cancer. The Active Breathing Coordinator (ABC) device theoretically decreases radiation exposure to the heart during radiation for…
- Conditions
- Breast Neoplasms, Carcinoma, Ductal, Adenocarcinoma
- Trial name
- NCT00321048
- Testing
- Active Breathing Coordinator
- Where
- United States
- Volunteers
- 57 people, healthy volunteers welcome
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins